There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Sanofi India Limited (Previously known as Aventis Pharma Limited) was incorporated in May 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 2012. The ...

Sanofi is reorganising its business units from seven to five in a bid to streamline its operations and ensure the success of its ambitious product launch plans. The revamp is the first major ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder. The US regulator has approved ...

Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a combination of its ...

Sanofi has made an interesting choice for its new head of R&D, turning to Houman Ashrafian, who has deep expertise in the biopharma industry, but can also draw on his most recent role as managing ...

Downstairs at Crane Kalman Gallery, in its exhibition celebrating the centenary of the painter Alan Lowndes (1921–78), one of his streetscapes is placed next to a street scene by L.S. Lowry. Shortly ...

The Conference of Great Lakes St. Lawrence Governors & Premiers (GSGP) hired Cathleen Domanico to serve as the organization’s full-time tourism director, according to a press release. Starting ...